![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » DEBIOVISION INC, A SPECIALITY PHARMACEUTICAL DEVELOPER JOINS THE DEBIO COMPANIES
DEBIOVISION INC, A SPECIALITY PHARMACEUTICAL DEVELOPER JOINS THE DEBIO COMPANIES
September 15, 2005
Debiopharm S.A., the independent drug development company specialising in oncology, endocrinology, CNS and niche products announced today the integration of its fully owned affiliate Debiovision, formerly known as H3 Pharma, a Quebec-based company focusing on the development of specialty pharmaceuticals into the Debio Group, following the purchase of all the outstanding shares of H3 Pharma in May 2005. Debiovision complements the existing synergistic companies in the Debio Group: Debiopharm, Debioinnovation and Debio R.P. in Switzerland and Debioclinic in France.
PR Newswire (http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/09-15-2005/0004108065&EDATE=)
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
21Oct